PFE Quote, Financials, Valuation and Earnings

Arvinas has a net margin of 21.63% compared to Pfizer's net margin of 43.91%. Pfizer's return on equity of 8.72% beat Arvinas's return on equity of -7.72%.

Pfizer has a consensus price target of $29.23, signalling upside risk potential of 18.77%. On the other hand Arvinas has an analysts' consensus of $19.36 which suggests that it could grow by 155.09%. Given that Arvinas has higher upside potential than Pfizer, analysts believe Arvinas is more attractive than Pfizer.

Pfizer has a beta of 0.582, which suggesting that the stock is 41.783% less volatile than S&P 500. In comparison Arvinas has a beta of 2.171, suggesting its more volatile than the S&P 500 by 117.131%.

Pfizer has a quarterly dividend of $0.43 per share corresponding to a yield of 6.91%. Arvinas offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pfizer pays 118.44% of its earnings as a dividend. Arvinas pays out -- of its earnings as a dividend.

Pfizer quarterly revenues are $13.7B, which are larger than Arvinas quarterly revenues of $188.8M. Pfizer's net income of $3B is higher than Arvinas's net income of $82.9M. Notably, Pfizer's price-to-earnings ratio is 17.83x while Arvinas's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pfizer is 2.25x versus 1.28x for Arvinas. Usually stocks with elevated PS ratios are considered overvalued.

Gilead Sciences has a net margin of 21.63% compared to Pfizer's net margin of 19.72%. Pfizer's return on equity of 8.72% beat Gilead Sciences's return on equity of 32.29%.

Pfizer has a consensus price target of $29.23, signalling upside risk potential of 18.77%. On the other hand Gilead Sciences has an analysts' consensus of $116.85 which suggests that it could grow by 6.37%. Given that Pfizer has higher upside potential than Gilead Sciences, analysts believe Pfizer is more attractive than Gilead Sciences.

Pfizer has a beta of 0.582, which suggesting that the stock is 41.783% less volatile than S&P 500. In comparison Gilead Sciences has a beta of 0.290, suggesting its less volatile than the S&P 500 by 71.014%.

Pfizer has a quarterly dividend of $0.43 per share corresponding to a yield of 6.91%. Gilead Sciences offers a yield of 2.84% to investors and pays a quarterly dividend of $0.79 per share. Pfizer pays 118.44% of its earnings as a dividend. Gilead Sciences pays out 816.25% of its earnings as a dividend. Neither of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Pfizer quarterly revenues are $13.7B, which are larger than Gilead Sciences quarterly revenues of $6.7B. Pfizer's net income of $3B is higher than Gilead Sciences's net income of $1.3B. Notably, Pfizer's price-to-earnings ratio is 17.83x while Gilead Sciences's PE ratio is 23.13x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pfizer is 2.25x versus 4.82x for Gilead Sciences. Usually stocks with elevated PS ratios are considered overvalued.

Moderna has a net margin of 21.63% compared to Pfizer's net margin of -907.48%. Pfizer's return on equity of 8.72% beat Moderna's return on equity of -29.23%.

Pfizer has a consensus price target of $29.23, signalling upside risk potential of 18.77%. On the other hand Moderna has an analysts' consensus of $47.59 which suggests that it could grow by 48.44%. Given that Moderna has higher upside potential than Pfizer, analysts believe Moderna is more attractive than Pfizer.

Pfizer has a beta of 0.582, which suggesting that the stock is 41.783% less volatile than S&P 500. In comparison Moderna has a beta of 1.845, suggesting its more volatile than the S&P 500 by 84.505%.

Pfizer has a quarterly dividend of $0.43 per share corresponding to a yield of 6.91%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pfizer pays 118.44% of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend.

Pfizer quarterly revenues are $13.7B, which are larger than Moderna quarterly revenues of $107M. Pfizer's net income of $3B is higher than Moderna's net income of -$971M. Notably, Pfizer's price-to-earnings ratio is 17.83x while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pfizer is 2.25x versus 3.97x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals has a net margin of 21.63% compared to Pfizer's net margin of 26.7%. Pfizer's return on equity of 8.72% beat Regeneron Pharmaceuticals's return on equity of 15.7%.

Pfizer has a consensus price target of $29.23, signalling upside risk potential of 18.77%. On the other hand Regeneron Pharmaceuticals has an analysts' consensus of $728.55 which suggests that it could grow by 32.96%. Given that Regeneron Pharmaceuticals has higher upside potential than Pfizer, analysts believe Regeneron Pharmaceuticals is more attractive than Pfizer.

Pfizer has a beta of 0.582, which suggesting that the stock is 41.783% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals has a beta of 0.325, suggesting its less volatile than the S&P 500 by 67.458%.

Pfizer has a quarterly dividend of $0.43 per share corresponding to a yield of 6.91%. Regeneron Pharmaceuticals offers a yield of 0.32% to investors and pays a quarterly dividend of $0.88 per share. Pfizer pays 118.44% of its earnings as a dividend. Regeneron Pharmaceuticals pays out -- of its earnings as a dividend.

Pfizer quarterly revenues are $13.7B, which are larger than Regeneron Pharmaceuticals quarterly revenues of $3B. Pfizer's net income of $3B is higher than Regeneron Pharmaceuticals's net income of $808.7M. Notably, Pfizer's price-to-earnings ratio is 17.83x while Regeneron Pharmaceuticals's PE ratio is 13.95x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pfizer is 2.25x versus 4.44x for Regeneron Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.